



**BRAWN**



7AA68

CIN NO.: L74899DL1985PLC022468

Date: 12.02.2021

The Deputy General Manager,  
Department of Corporate Relationship,  
BSE Limited,  
Floor 25, Phirozee Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400001

**SCRIP CODE: 530207**

**Sub: Outcome of the Meeting of the Board of Directors held today, 12<sup>th</sup> February, 2021 as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended 31<sup>st</sup> December. 2020.**

**Dear Sir/ Ma'am,**

Pursuant to Regulations 30 read with Schedule III, Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. 12<sup>th</sup> February, 2021 to consider and approve the following:

1. Standalone Unaudited Financial Results of the Company for the quarter and nine month ended December 31<sup>st</sup>, 2020.
2. Limited Review Report by the Statutory Auditors of the Company. The Board took note that the Statutory Auditor have expressed an unqualified and unmodified audit opinion.
3. Appointment of Mr. Amit Kumar, as Manager (Key Managerial Personnel), for the term of 5 years.

The meeting of the Board of Directors commenced at 3:30 P.M. and concluded at 4:30 P.M.

We request you to kindly take the above information on record.

Thanking you,

For BRAWN BIOTECH LIMITED

*Sharma*  
Priyanka Sharma  
Company Secretary & Compliance Officer  
Encl: As above



**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

*... for better life*

**Regd. Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: solution@brawnbiotech, Website : www.brawnbiotech.com

**Export Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

**Corporate Office :** Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram (Haryana) 122001, Tel: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com

**Works :** 13, Industrial Area, N.I.T., Faridabad - 121001 (Haryana) Tel.: +91-8010416849/48



**BRAWN**



6B338

CIN NO.: L74899DL1985PLC022488

BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022488 REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002							
STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER 2020							
Sr.	Particulars	Quarter ended			Nine Months ended		Rs. In Lacs
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	Year Ended
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	31.03.2020
							Audited
1	Revenue from operations						
	Revenue from operations	1478.22	969.95	1322.29	3191.40	4294.97	4961.62
	Other Income	0.03	-	1.72	0.08	6.21	17.09
	<b>Total Revenue</b>	<b>1478.26</b>	<b>969.95</b>	<b>1324.01</b>	<b>3191.48</b>	<b>4301.18</b>	<b>4978.71</b>
2	Expenses						
a	Cost of material consumed	-	-	-	-	-	-
b	Purchase of stock-in-trade	1488.68	867.37	1191.42	3050.30	3802.90	4215.31
c	Change in inventories of finished goods, work in progress and stock in trade	(139.26)	(6.15)	(32.07)	(148.66)	(25.11)	(5.02)
d	Employee Benefit expenses	61.15	64.69	116.11	166.45	224.01	308.28
e	Depreciation and amortisation expenses	0.80	0.90	0.96	2.58	2.55	3.47
f	Finance Cost	0.23	1.24	0.52	1.72	3.28	4.94
g	Other expenses	48.42	33.52	41.03	113.93	173.31	369.75
	<b>Total Expenses</b>	<b>1460.01</b>	<b>961.57</b>	<b>1318.77</b>	<b>3186.31</b>	<b>4180.94</b>	<b>4896.73</b>
3	Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)	18.24	8.37	5.24	5.17	120.24	81.98
4	Other Income	-	-	-	-	-	-
5	Profit from ordinary activities before exceptional items (3-4)	18.24	8.37	5.24	5.17	120.24	81.98
6	Exceptional Items	-	-	-	-	-	-
7	Profit from ordinary activities before tax (5-6)	18.24	8.37	5.24	5.17	120.24	81.98
8	Tax Expenses	-	-	1.56	-	28.84	22.85
9	Profit (Loss) for the period from continuing operations (7-8)	18.24	8.37	3.68	5.17	91.40	59.13
10	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Profit (Loss) for the period (9+12)	18.24	8.37	3.68	5.17	91.40	59.13
14	Other Comprehensive Income	(0.09)	(0.17)	0.96	(6.67)	(7.07)	1.30
	<b>Total Comprehensive Income</b>	<b>18.15</b>	<b>8.20</b>	<b>4.64</b>	<b>(1.50)</b>	<b>84.32</b>	<b>60.43</b>
15	Details of equity share capital	300.03	300.03	300.03	300.03	300.03	300.03
	Paid-up equity share capital	-	-	-	-	-	-
	Face value of equity share capital	-	-	-	-	-	-
16	Reserve excluding Revaluation Reserve	-	-	-	-	-	-
17	Earnings per share						
i	Basic earnings per share	0.60	0.27	0.15	(0.05)	2.81	2.01
ii	Diluted earnings per share	0.60	0.27	0.15	(0.05)	2.81	2.01

**NOTES :-**

- Results for the quarter ended on 31st December, 2020 were reviewed by the Audit committee and then approve by the Board of Directors at their meeting held on 12 February, 2021.
- The Statutory Auditors carried out the limited review for quarter ended 31st December, 2020. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Un-audited Financial Results for the quarter ended on 31-12-2020 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech Limited

*[Signature]*  
Brij Raj Gupta  
Director  
DIN No. 00974969  
Date: 12.02.2021  
Place: Delhi

**BRAWN BIOTECH LTD.**  
(Formerly Known as Brawn Pharmaceuticals Ltd.)

*... for better life*

**Regd. Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

**Export Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

**Corporate Office :** Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com

**Works :** 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



**RAJIV UDAI & ASSOCIATES**  
CHARTERED ACCOUNTANTS

To,  
The Board of Directors of  
Brawn Biotech Limited

We have reviewed the accompanying statement of unaudited financial results of Brawn Biotech Limited for the period ended 31st December 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Rajiv Udai & Associates  
Chartered Accountants

Firm Registration No. 018764N

*Rajeev Jain*

Rajeev Jain  
Partner

Membership No. 099767

UDIN: 21099767AAAABM1944



Place: Delhi

Date: 12-02-2021